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Abstract
Objective: Accurate preoperative staging is essential to provide the best treatment for lung cancer. The objective of the present study was to
determine agreement between preoperative and surgical—pathological staging and to analyse the impact of any disparity on treatment.
Methods: This is a descriptive study of a series of 176 lung cancer cases treated by surgery between 2005 and 2007. Preoperative stagingwas based
on clinical information and computed tomography (CT), positron emission tomography (PET), PET-CT, bronchoscopy and mediastinoscopy. In all
cases, surgical—pathological staging was based on the analysis of surgical samples and the findings during surgery. Both preoperative and
pathological stage determination were based on the TNM (tumour, node, metastasis) classification established in 1997. Concordance was
measured by calculating agreement rates and the kappa value. Results: Preoperative and surgical—pathological staging agreed in 102 cases, an
agreement rate of 58% and kappa value of 0.54 (95% confidence interval (CI) 0.44—0.63). The highest kappa value (0.68, 95% CI 0.53—0.82) was
obtained in stage IA patients. Patients who underwent PET or PET-CT had a better kappa index (0.56, 95% CI 0.45—0.67, vs 0.39, 95% CI 0.21—
0.56). Surgical—pathological staging validated surgery in 145 cases (82%), while 21 (12%) were revised to stage IIIA N2 and 10 (6%) to non-surgical
stages. Conclusions:Global agreement between preoperative and surgical—pathological staging wasmoderate. The best agreement was found in
stages IV and IA.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Accurate preoperative staging in bronchogenic carcinoma
is essential in determining the true extent of disease;
moreover, it is crucial if we are to provide patients with
optimal treatment and a realistic prognosis. It is therefore
imperative that preoperative staging coincide closely with
pathological staging, which uses information obtained during
surgery to provide the most accurate picture of disease
extension. Preoperative and surgical—pathological staging
are currently based on the revised tumour-node-metastasis
(TNM) classification system established by the American Joint
Committee on Cancer (AJCC) and the International Union
Against Cancer (UICC), which has been in effect since 1997
[1], although revised criteria have been proposed for 2009
[2]. According to the published studies, agreement rates
range from 35% to 50% [3].
Preoperative staging has improved markedly in recent
years with the emergence of new tools such as positron
emission tomography (PET), used alone or in with computed
tomography (PET-CT), virtual bronchoscopy, endobronchial
ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) and endoscopic ultrasound-guided fine-needle aspira-
tion of the upper digestive tract (EUS-FNA).
www.elsevier.com/locate/ejcts
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The aim of the present study was to determine the degree
of agreement between preoperative and surgical—patholo-
gical staging in bronchogenic carcinoma and to analyse the
consequences of diagnostic connection with the surgical
treatment carried out. This is not a study to assess, compare
or validate tools like PET, CT, mediastinoscopy or EBUS;
furthermore, this study does not expect to validate
predictors of the descriptors T, N or M.
This is only a quality study of the staging carried out by a
hospital lung cancer board (Lung Functional Unit) and the
impact of these decisions in the surgical treatment
performed.
2. Material and methods
2.1. Sample
This is a descriptive study of 176 patients diagnosed with
lung cancer and treated by surgery with curative intent at our
hospital between July 2005 and August 2007. Of the 176
cases, 173 had no prior history of lung cancer while three
were second lung tumours (two of which were metachronous
and one synchronous).
2.2. Inclusion and exclusion criteria
The initial sample included 190 patients who underwent
surgery with curative intent for lung cancer. Prior to surgery,
all patients presented a lung nodule suggestive of malignancy
or a histologically confirmed neoplasm. Exclusion criteria
were as follows: inability to determine one of the TNM
descriptors during preoperative or pathologic staging (five
cases); complete pathological response after neo-adjuvant
treatment (two cases); exploratory thoracotomy (six cases),
and stage 0 (one case). During the inclusion period, six
additional patients underwent surgery due to a lung tumour
recurrence while one patient had surgery for lungmetastasis;
none of these cases were included in the study.
All 176 patients in our series underwent both preoperative
and pathological staging according to the guidelines
published in the 6th edition of the TNM classification of
malignant tumours, accepted by the UICC and AJCC for lung
cancer and in effect since 1997 [1]. In the present study,
preoperative staging was performed prior to surgery with
curative intent under the supervision of the lung tumour
board at our hospital. The tumour committee consists of a
multidisciplinary team with specialists in respiratory med-
icine, radiodiagnostics, nuclear medicine, thoracic surgery,
pathology, medical oncology and radiation oncology. Staging
was performed by evaluating data from patient medical
records and physical examination, bronchoscopy, chest
radiograph, contrast-enhanced CT of the chest and upper
abdomen, PET in two cases (1%), PET-CT in 135 cases (77%),
mediastinoscopy in seven cases (4%) and brain magnetic
resonance imaging (MRI) in cases with adenocarcinoma and/
or clinical suspicion of advanced stage. Bone scintigraphy was
not performed because PET scans are reported to be better
than scintigraphy at detecting bone metastasis [4].
To determine whether the primary tumour (T) had invaded
the mediastinum, we used the following criteria for no
invasion: less than 3 cm of tumour in contact with the
mediastinum, presence of a fatty layer between the tumour
and the mediastinum and less than 908 of circumferential
contact with the aorta [5]. Cytological samples were
obtained by bronchoscopic aspiration. Whenever possible,
biopsy of the primary tumour was performed by broncho-
scopy and/or CT-guided fine-needle aspiration (FNA) to
obtain histological diagnosis prior to surgery.
For lymph node staging (N), all patients with a PETor PET-
CTscan without evidence of thoracic or supraclavicular nodal
uptake were considered cN0 as were patients with nodal
uptake (after visual and semi-quantitative analysis and
determination of the maximum standard uptake value
(SUVmax)) of the radiolabelled glucose analogue fluorodeox-
yglucose (FDG) at the mediastinal level but with a negative
biopsy on mediastinoscopy. Evidence of uptake at the hilar
level on the PETor PET-CT scan was considered sufficient for
cN1 (hilar lymph node involvement) classification. Patients
with positive mediastinal nodes on biopsy were considered
cN2, although in certain cases we elected to perform surgery
despite nodal involvement, for these cases, uptake identified
by PETor PET-CTwas deemed sufficient for cN2 classification.
To confirm the presence of neoplastic disease, all patients
with evidence of mediastinal node uptake on PET or PET-CT
underwent mediastinoscopy. If no evidence of disease was
found on pathological examination of the resected samples,
the patient was considered eligible for surgery, provided that
assessment of the Tand M descriptors supported this option.
However, patients with confirmed nodal involvement were
prescribed neo-adjuvant chemotherapy (with or without
radiotherapy), after which restaging was performed. In cases
without PET or PET-CT scan, nodal involvement detected by
CTscan was considered pathological if the smallest diameter
was greater than 1 cm in all nodal stations, except for the
subcarinal level, where the minimum was 1.5 cm.
PETor PET-CTscans were used to assess distant metastasis
(descriptor M). If FDG uptake suggestive of malignancy was
detected in any region of the body, a comprehensive physical
examination—including additional imaging tests and extrac-
tion of histological material (generally with fine-needle
aspiration)—was performed. Other tests to rule out distant
metastasis were performed in certain cases. In this study, all
cases included with metastasis underwent resection of the
metastatic tumour prior to thoracic surgery.
Patients at preoperative stages I, II and IIIAwith hilar node
involvement were deemed surgical candidates. Under
certain conditions, other patients were also accepted for
surgery: stage IIIA patients with mediastinal node involve-
ment (major haemoptysis or involvement of a single station
on PET or PET-CT with reduced metabolic activity of the
affected nodes after neo-adjuvant treatment); stage IIIB
cases with a diseased satellite node in the same lobe or
vertebral involvement without mediastinal node involve-
ment; stage IV patients with a single resectable brain
metastasis; and patients with a single resectable suprarenal
metastasis.
The 176 cases in our study underwent thoracotomy, lung
resection and hilar and mediastinal lymphadenectomy. The
lymphadenectomy was more than sampling [6,7]; all lymph
nodes that were seen during surgery were removed. At least,
lymph node stations must be explored and the lymph node
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removed at the anatomic level of the hilum and mediastinum
(topographic) that correspond to the specimen (the lobe with
the tumour) or lung section to be extirpated; at least three
hilar lymph nodes and three mediastinal lymph node stations
from these levels should be evaluated pathologically.
Fourteen patients (8%) received chemotherapy prior to
surgery.
To assess the resected samples for pathology, all lymph
nodes were individualised, fixed in 10% formaldehyde and
completely embedded in paraffin. The paraffin blocks were
cut into numerous 3-mm sections (from two to eight sections
per block) and then subjected to deparaffination and
rehydration followed by conventional haematoxylin and
eosin staining. Histological evaluation was performed by a
single observer. Pathological staging, which followed the
same TNM classification system used for preoperative
staging, took into consideration information gathered during
surgery.
2.3. Data collection
A rigorous protocol which included the following informa-
tion: administrative data, demographic data, toxic habits,
co-morbidities, additional tests performed, treatments prior
to surgery, preoperative staging, surgery performed, patho-
logical staging, histology and tumour location was developed
for patient data collection.
2.4. Statistical analysis
Statistical analysis included descriptive statistics and
agreement analysis. To compare the results of preoperative
and pathological staging, the kappa index and the agreement
rate (the number of cases in which preoperative and
pathological staging coincided divided by the number of
cases that underwent preoperative staging) were calculated.
We have calculated global kappa and k individual kappas for
each category, named weighted kappa by Cohen [8].
According to published criteria, a kappa value less than 0
implies poor agreement; 0—0.2 indicates slight agreement;
0.21—0.4, fair; 0.41—0.6, moderate; 0.61—0.8, substantial
and greater than 0.8 almost perfect agreement [9].
Statistical analysis was performed with SPSSW 12.0 (Statis-
tical Package for the Social Sciences, SPSS Inc., Chicago, IL,
USA). All patients signed the informed consent form and our
institutional ethics committee on human research approved
the study.
3. Results
Descriptive analysis of the population revealed 158 men
(90%) and 18 women (10%), with a mean age of 62 years and a
median age of 63 (range, 40—81 years) and a standard
deviation of 9.4 years. Of these 176 patients, 89% were
current or previous smokers and 1% were passive smokers. In
addition, 47% had a prior history of respiratory disease and
46% a history of cardiocirculatory problems. Sixteen percent
of the sample had a prior history of cancer. The remaining
characteristics are described in Table 1. All patients under-
went both preoperative and pathological staging (Table 2).
Stage IB was the most common preoperative stage and stage
IA the most common pathological stage. Mean time between
preoperative staging and surgery was 21 days, with a median
of 20 days (range, 2—66 days).
Preoperative and pathological staging coincided in 102
cases (Table 2) for an overall agreement rate of 58% and
kappa value of 0.54, 95% CI 0.44—0.63. The agreement rate
and kappa value for each stage are shown in Table 3. Stage IV
had the highest agreement (100%), followed by stage IA
(75%), although the best kappa index was observed in stage IA
(0.68, 95% CI 0.53—0.82).
Preoperative understaging occurred in 53 cases (30%) and
overstaging in 21 cases (12%). Of the 53 understaged cases,
pathological examination confirmed that 22 (41% of that
group) were surgical stages, while 21 (40%) were stage IIIA
with mediastinal node involvement and 10 (19%) were stages
IIIB or IV. All the overstaged cases were surgical candidates.
Preoperative and pathological staging for the descriptor T
(primary tumour) coincided in 127 cases, for an agreement of
I. Macia et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 540—545542
Table 1
Patient characteristics.
n a %b
Histology Adenocarcinoma 66 38
Squamous cell carcinoma 58 33
Bronchioloalveolar adenocarcinoma 17 10
Large-cell carcinoma 16 9
Small-cell carcinoma 4 2
Miscellaneous 15 8
Tumour location Upper left lobe 56 32
Upper right lobe 53 30
Lower left lobe 36 21
Lower right lobe 25 14
Main and intermediate bronchi 4 2
Middle lobe 2 1
Resection performed Segmentectomy 7 4
Standard and extended lobectomy 144 82
Bilobectomy 7 4
Standard and expanded pneumonectomy 18 10
a n, number of patients.
b %, percentage of patients.
Table 2
Distribution by preoperative and pathological staging.
cTNMa Total %d
IA IB IIA IIB IIIA c IIIB IV
pTNMb
IA 38 10 0 0 0 0 0 48 27
IB 4 33 0 4 2 0 0 43 25
IIA 1 0 1 1 1 0 0 4 2
IIB 1 15 0 18 1 2 0 37 21
IIIA 5 8 1 8 6 0 0 28 16
IIIB 0 0 0 1 2 1 0 4 2
IV 2 2 0 1 1 1 5 12 7
Total 51 68 2 33 13 4 5 176 100
%d 29 39 1 19 7 2 3 100
a cTNM, preoperative staging.
b pTNM, surgical—pathological staging.
c The 13 cases at preoperative stage IIIA include 3 patients with hilar node
involvement and 10 with diseased mediastinal nodes. The 28 cases at patho-
logical stage IIIA include 2 with affected hilar nodes and 26 with mediastinal
node involvement.
d Percentage of cases.
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72% and a kappa value of 0.61 (95% CI 0.50—0.71). For the
descriptor N (nodal involvement) agreement between
preoperative and pathological staging was confirmed in
123 cases, an agreement of 69% and kappa index of 0.34 (95%
CI 0.23—0.44).
For the group of patients who underwent a PET scan (PET
alone or PET-CT), in 137 cases, agreement was 57% with a
kappa value of 0.56 (95% CI 0.45—0.67). In contrast,
agreement for those who did not undergo PET (39 cases)
was 62%, with a kappa value of 0.39 (95% CI 0.21—0.56).
Taking CIs into consideration, the differences between these
two groups were not significant; p > 0.05.
After establishing the histological type of the resected
tissue, we assessed agreement between preoperative and
pathological staging as a function of tumour histology.
Agreement between pre- and postoperative histological type
was not assessed. The highest agreement (100%) and kappa
values (1) were observed in bronchioloalveolar adenocarci-
noma. Large-cell carcinoma had the second highest agree-
ment (75%) and kappa values (0.74, 95% CI 0.42—1).
Agreement rates for squamous cell carcinoma and adeno-
carcinoma were 55% and 47%, respectively, with kappa values
of 0.55 (95% CI 0.38—0.72) and 0.42 (95% CI 0.26—0.57).
The lowest kappa value (0.14, 95% CI 0.01—0.26) occurred
in the group that included the few patients with small-cell
lung cancer. Of these four patients, there were three patients
with localised small lung nodule without affected lymph
nodes and without metastasis prior to surgery and one
patient in whom the histology of small-cell lung cancer was
discovered after surgery.
Tumours located in the lower right lobe gave a higher
agreement (68%) and the highest kappa value, 0.67 (95% CI
0.41—0.93). The lowest kappa value (0.39, 95% CI 0.21—0.58)
was observed in tumours of the lower left lobe. The 162
patients who did not receive neo-adjuvant chemotherapy
presented a higher kappa value (0.53, 95% CI 0.43—0.62, vs
0.24, 95% CI 0.04—0.53) than those who received chemother-
apy prior to surgery.
All patients underwent surgery, as described in Section
2.2. The pathology report confirmed that surgery was
correctly indicated in 91 stage I cases, 41 stage II cases
and two stage IIIA cases with nodal involvement at the hilum;
this in addition to the selected cases at non-surgical stages
that were accepted for surgery and confirmed the stage
pathologically: five at stage IIIA with mediastinal lymph node
involvement, one at stage IIIB and five at stage IV. In other
words, 145 cases (82%) correctly underwent surgery accord-
ing to their final pathological stage. Of the remaining 31
cases, 21 were pathological stage IIIA with diseased
mediastinal nodes (12% of all cases) and 10 were stage IIIB
or IV (6% of the total) (Fig. 1).
4. Discussion
In lung cancer, a preoperative staging that approximates
the real anatomical extent of disease allows, a priori, each
patient to receive optimal treatment. Moreover, with proper
staging, the prognosis is realistic. Pathological staging, which
includes information gathered during surgery, is the current
gold standard in determining disease extension and is one of
the main prognostic factors. As a result, obtaining good
agreement between preoperative and pathological staging—
that is, a high number of cases in which preoperative staging
reflects reality—is essential.
The characteristics of the patients included in this study
are similar in many ways to those we find in our daily practice
in Spain, as evidenced by comparing our sample with the
patient data provided by the member hospitals of the
Bronchogenic Carcinoma Cooperative Group (GCCB-S) of the
Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
[3]. Our sample is similar to the GCCB-S group in many
respects: men account for a large percentage of patients in
both groups, the mean age (62 years vs 64 years in the GCCB-
S) is similar, as is the percentage of current or past smokers
(89% vs 87%), and both groups have high rates of respiratory
or cardiocirculatory co-morbidities. In addition, distribution
among early and late stages is similar in both series, with
stage IB being the most common group on preoperative
staging in both series. However, differences can be found in
histological type—adenocarcinoma was the most common
cancer in our study—and in the distribution of lung
resections, with a lower percentage of pneumonectomies
and more lobectomies in our series [3].
A review of the literature shows that overall agreement
between preoperative and pathological staging is low, with
reported rates ranging from 22% to 47% [3,10—13] and a
kappa value of approximately 0.25 [3]. However, most of
these studies did not use a PET scan or PET-CT fusion for
preoperative staging. A PETor PET-CTwas performed on most
patients in our series, mostly as a consequence of the
increasingly routine use of such scans at our hospital. The
overall agreement (58%) and kappa index (0.54, 95% CI 0.44—
0.63)—both of which indicate moderate agreement—
observed in our study are better than the figures reported
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Table 3
Agreement by stage.
Stage Agreement
rate (%)
Kappa value 95% confidence
intervals
IA 75 0.68 0.53—0.82
IB 49 0.42 0.28—0.56
IIA 50 0.32 0.18—0.46
IIB 55 0.39 0.25—0.54
IIIA 46 0.21 0.08—0.34
IIIB 25 0.23 0.09—0.38
IV 100 0.57 0.44—0.70
Fig. 1. Distribution of cases by pathological stage and clinical impact.
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in other studies. While it is true that agreement was slightly
higher in those group patients who did not undergo PET than
in those who did, results of the derived kappa index show
better agreement in the PET group (0.56, 95% CI 0.45—0.67,
vs 0.39, 95% CI 0.21—0.56), although this difference was not
significant. This study was not designed to compare PET or
PET-CT versus no PET with regard to agreement between
preoperative and surgical—pathological staging.
Although PET can be used to assess nodal stations
throughout the body, fusion with CT makes more precise
determination of the anatomical location. This is possible
because fusion scans provide both morphological and
metabolic information while CTalone is exclusively morpho-
logic. In addition, with PET-CT, it is possible to identify
disease in locations that were not initially suspected of
involvement, especially nodal groups. Previously, our group
carried out a preliminary study of 68 patients evaluated by
PET-CT fusion and we found a high specificity (94%) and a
negative predictive value (97%) in mediastinal staging with
no association between SUVmax and mediastinal involve-
ment by either PET-CTor surgery. However, some groups have
found SUVmax to be a prognostic factor in lung cancer; with a
higher SUVmax associated with a worse survival index [14].
Attempts have also been made to establish a specific SUVmax
cut-off point that would indicate a higher probability of
malignancy [15].
Considering all this, we can deduce that one factor that
allows us to achieve a closer approximation to the real extent
of the disease is the routine use of PET-CT for preoperative
staging [16]. Although PET-CT is not a substitute for other
tests, it can serve as a guide for other exploratory techniques
that obtain histological material from the mediastinum and
the hilum, such as mediastinoscopy and endobronchial
ultrasound and endoscopic ultrasound of the upper digestive
tract, serving to increase the yield of these techniques. The
aim of such techniques is to serve as a complement to
improve preoperative staging.
The highest levels of agreement were found at stage I,
especially stage IA, with our results similar to those reported
in the literature: there was agreement of approximately 60%
for stage I and 75% for stage IA [17,18]; with kappa index of
approximately 0.70 for stage IA [19]. On the other hand,
agreement in more advanced stages—such as stage III—was
worse. Stage IV is a special situation because extirpation of
the metastasis prior to thoracic surgery influences agree-
ment.
An analysis of the descriptors Tand N show higher levels of
agreement for T than for N, a fact previously described in the
literature, with agreement rates of approximately 70% for
the descriptor T and 50% for N [10]. In terms of the kappa
index, the results presented here are better than previously
reported series in terms of T and N [3]. A limitation of this
type of study is the ethical impossibility of fully examining
the pathological expression of metastasis since only those
organs with a clinical suspicion of metastasis are examined.
It is worth pointing out that agreement analysis of all
variables shows the best agreement in patients who did not
receive neo-adjuvant chemotherapy and in those with
bronchioloalveolar adenocarcinoma of the lower right lobe.
The excellent agreement achieved in the 17 cases of
bronchioloalveolar adenocarcinoma is surprising given the
considerable reported rate of false negatives on PET scans in
such tumours [20]. It would be interesting to see if this
agreement is maintained when we have a larger series of
patients.
Surgery with curative intent in small-cell lung cancer is a
matter of controversy. In this study, the few patients with
small-cell lung cancer were selected cases with localised
neoplasm or patients in whom the histology of small-cell lung
cancer was discovered after surgery.
In cases with no agreement between preoperative and
pathological staging, our analysis showed that the tendency
was for preoperative understaging, a fact described pre-
viously in the literature [3,17]. Notably, about 60% of
understaged cases in our series were, in the end, either non-
surgical or initially non-surgical, mostly stage IIIA with
mediastinal node involvement. When analysing false nega-
tives on PET scans, it is important to keep in mind the poor
sensitivity such scans have for detecting nodes smaller than
8 mm, necrosis or cystic components and certain histological
types such as bronchioloalveolar adenocarcinoma. All of the
overstaged cases were surgical candidates and so staging
differences did not affect the therapeutic approach.
Despite the battery of modalities and the use of a variety
of different techniques over the years, the information
presented here demonstrates that some disease remains
undetected. The increasing adoption of virtual broncho-
scopy, endobronchial ultrasound and endoscopic ultrasound
of the upper digestive tract with FNA as well as tools such as
molecular markers should be considered as additional
modalities to evaluate the true extent of disease
[18,21,22]. Moreover, given the low rate of preoperative
overstaging, few surgical candidates are excluded from
surgery owing to doubts about resectability.
The most important aspect of the present study is to
determine how lack of agreement influences patient
treatment [18]. Despite the fact that the level of agreement
(58%) in our study was only moderate, 82% of patients
received the appropriate treatment. In many cases, stage
migration occurred within surgical stages. However, post-
surgical evaluation identified 12% of patients in our sample at
stage IIIA with mediastinal node involvement who should
have received neo-adjuvant treatment followed by subse-
quent restaging. In addition, 6% of patients should not have
undergone surgery at all because they were pathological
stage IIIB or IV (Fig. 1).
In terms of possible bias, the inclusion of patients with and
without preoperative PET and patients who received neo-
adjuvant treatment gave us a heterogeneous group of
patients. However, such a diverse sample provides us with
a broad view of preoperative and pathological agreement in
surgically treated lung cancer.
In conclusion, agreement analysis of preoperative and
pathological staging in lung cancer reveals the crude reality:
despite our best efforts, preoperative staging is incorrect in
approximately half of all patients. Nevertheless, the
introduction in recent years of new imaging modalities and
techniques has helped—and will continue to help—improve
staging. Fortunately, our analysis of the impact of differences
between preoperative and pathological staging on patient
treatment allows us to make a relatively benign conclusion:
surgery is appropriately indicated in most cases and only a
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small portion of patients should have received a different
treatment, at least in regards to the initial treatment. We
believe that efforts aimed at extending and standardising
newly emerging techniques should continue, and information
that such techniques provide should be added to data
collected by current techniques and should also included in
staging protocols [23]. Moreover, more research needs to be
done to discover new and better ways to assess disease
extent and complement the information currently obtained
by pathological staging.
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